Growth Metrics

Eli Lilly (LLY) Net Income towards Common Stockholders Growth (1y) (2010 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (1y) (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 168.07%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn -52.40%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn -45.93%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -182.77%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 5.14%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 53.69%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn -
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 8.81%
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 168.07%
Dec 31, 2025 50.52%
Sep 30, 2025 475.34%
Jun 30, 2025 90.78%
Mar 31, 2025 23.01%
Dec 31, 2024 101.43%
Sep 30, 2024 1,790.42%
Jun 30, 2024 68.27%
Mar 31, 2024 66.77%
Dec 31, 2023 12.98%
Sep 30, 2023 -103.95%
Jun 30, 2023 85.11%
Mar 31, 2023 -29.32%
Dec 31, 2022 12.26%
Sep 30, 2022 30.77%
Jun 30, 2022 -31.48%
Mar 31, 2022 40.40%
Mar 31, 2019 7,231.67%
Dec 31, 2018 100.24%
Sep 30, 2018 -89.94%
Jun 30, 2018 -102.81%
Mar 31, 2018 145.31%
Dec 31, 2017 -300.76%
Sep 30, 2017 -28.59%
Jun 30, 2017 34.81%
Mar 31, 2017 -125.18%
Dec 31, 2016 68.00%
Sep 30, 2016 -2.71%
Jun 30, 2016 24.45%
Mar 31, 2016 -16.88%
Dec 31, 2015 11.07%
Sep 30, 2015 59.75%
Jun 30, 2015 -18.09%
Mar 31, 2015 -27.26%
Dec 31, 2014 -42.41%
Sep 30, 2014 -58.39%
Jun 30, 2014 -39.19%
Mar 31, 2014 -52.98%
Dec 31, 2013 -12.25%
Sep 30, 2013 -9.31%
Jun 30, 2013 30.60%
Mar 31, 2013 53.10%
Dec 31, 2012 -5.30%
Sep 30, 2012 7.30%
Jun 30, 2012 -22.86%
Mar 31, 2012 -4.24%
Dec 31, 2011 -26.10%
Sep 30, 2011 -5.11%
Jun 30, 2011 -11.24%
Mar 31, 2011 -15.40%
Dec 31, 2010 27.77%
Sep 30, 2010 38.40%
Jun 30, 2010 16.44%
Mar 31, 2010 -4.95%